Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIPENT vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Hairy cell leukemia,Cutaneous T-cell lymphoma
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
5 mg/m2 intravenously over 20-30 minutes every 3 weeks.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal elimination half-life is approximately 5-8 hours in patients with normal renal function. Clinically, the half-life may be prolonged in renal impairment, requiring dose adjustments.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Primarily metabolized by the liver via deamination by adenosine deaminase (ADA).
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Primarily renal excretion; approximately 50-70% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination accounts for <5%.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Approximately 90-95% bound to serum albumin.
47% bound to human plasma proteins, primarily albumin.
Volume of distribution (Vd) is approximately 0.4 L/kg, indicating distribution primarily into extracellular fluid.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Not applicable; Nipent is only administered intravenously with 100% bioavailability via that route. Oral bioavailability is negligible and not clinically relevant.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
Contraindicated if creatinine clearance < 60 m L/min. For Cl Cr 60-90 m L/min: reduce dose to 2.5 mg/m2. Not recommended if Cl Cr < 60 m L/min.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
No specific dose adjustment guidelines for Child-Pugh class A or B. Use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Safety and efficacy not established in pediatric patients <18 years. No recommended weight-based dosing.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustments recommended for elderly based on age alone; monitor renal function closely as older patients are more likely to have decreased creatinine clearance.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
WARNING: NIPENT (pentostatin) can cause severe bone marrow suppression, leading to neutropenia, thrombocytopenia, and anemia. Fatal hemorrhagic events and infections have occurred. Use with caution in patients with impaired renal function.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Bone marrow suppression: monitor blood counts regularly,Renal toxicity: assess renal function before and during therapy,Hepatotoxicity: monitor liver function tests,Pulmonary toxicity: observe for signs of pneumonitis,Embryofetal toxicity: advise patients of reproductive potential to use effective contraception,Increased risk of infection: avoid live vaccines
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
Hypersensitivity to pentostatin or any component of the formulation,Severe hepatic impairment,Pregnancy (risk of fetal harm)
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
Grapefruit and grapefruit juice should be avoided due to potential CYP3A4 inhibition. No other significant food interactions are reported.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Pregnancy Category D. First trimester: potential teratogenicity (based on animal studies and limited human data). Second and third trimesters: risk of fetal harm (e.g., myelosuppression, growth restriction).
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
Contraindicated during breastfeeding. M/P ratio unknown; pentostatin is excreted in human milk with potential for serious adverse reactions in nursing infants.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No established safe dose; avoid use in pregnancy. If unavoidable, consider reduced dosing based on increased volume of distribution and renal clearance, but individualize with close monitoring for toxicity.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
Administer with aggressive pre-hydration (≥2L NS) and urine alkalinization to prevent nephrotoxicity. Monitor for severe myelosuppression, especially neutropenia. Consider leukapheresis for high-risk patients to prevent tumor lysis syndrome. Dose adjustment required for renal impairment (Cr Cl <60 m L/min).
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
Drink at least 2-3 liters of water daily to protect kidneys.,Report any unusual bleeding, bruising, or signs of infection (fever, sore throat) immediately.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during and for 6 months after therapy.,Do not receive live vaccines during treatment.,Report any new or worsening shortness of breath or chest pain.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIPENT vs CLOLAR, answered by our medical review team.
NIPENT is a Antineoplastic Agent that works by Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIPENT and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIPENT is: 5 mg/m2 intravenously over 20-30 minutes every 3 weeks.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIPENT and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIPENT is classified as Category C. Pregnancy Category D. First trimester: potential teratogenicity (based on animal studies and limited human data). Second and third trimesters: risk of fetal harm (e.g., myelosuppre. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.